Department of Otolaryngology-Head and Neck Surgery.
Department of Epidemiology and Biostatistics.
Otol Neurotol. 2020 Apr;41(4):e494-e500. doi: 10.1097/MAO.0000000000002561.
The aim of this article is to develop and validate a disease-specific, patient-reported outcome measure for vestibular migraine.
Tertiary care vestibular center.
Adult patients with definite or probable vestibular migraine per Barany Society Criteria.
This was a prospective cohort study. VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) was developed with expert input, literature review, and patient feedback. VM-PATHI scores were compared between those with vestibular migraine and controls, across several time points, and to other dizziness and quality of life (QoL) measures.
A 25-item questionnaire was developed. Cronbach's α was high at 0.92. Test-retest reliability was excellent (r = 0.90, p < 0.001). Scores were much higher in patients with vestibular migraine (mean 42.5, SD = 16.1) than control patients (mean = 9.6, SD = 8.5). VM-PATHI scores were responsive to treatment (p = 0.01). Scores were well correlated with general QoL, depression, and anxiety scores. Scores were also correlated with the Dizziness Handicap Inventory (r = 0.69). An exploratory factor analysis was performed, which revealed 6 distinct factors that corresponded well to different aspects of disease-related symptomatology.
VM-PATHI is a valid, reliable, and responsive measure of disease severity in vestibular migraine.
本文旨在开发和验证一种针对前庭性偏头痛的特定疾病、患者报告的结局测量工具。
三级护理前庭中心。
符合巴兰尼学会标准的明确或可能的前庭性偏头痛成年患者。
这是一项前瞻性队列研究。VM-PATHI（前庭性偏头痛患者评估工具和残疾量表）是在专家意见、文献回顾和患者反馈的基础上开发的。在多个时间点，将 VM-PATHI 评分与前庭性偏头痛患者和对照组进行比较，并与其他头晕和生活质量（QoL）测量进行比较。
开发了一个 25 项的问卷。克朗巴赫 α 值很高，为 0.92。测试-重测信度非常好（r=0.90，p<0.001）。前庭性偏头痛患者的评分明显高于对照组患者（平均 42.5，标准差=16.1）（平均=9.6，标准差=8.5）。VM-PATHI 评分对治疗有反应（p=0.01）。评分与一般 QoL、抑郁和焦虑评分高度相关。评分也与眩晕障碍量表相关（r=0.69）。进行了探索性因子分析，结果显示 6 个不同的因子与疾病相关症状的不同方面相对应。
VM-PATHI 是一种针对前庭性偏头痛严重程度的有效、可靠和敏感的测量工具。
